We identified pasireotide as the only FDA-approved drug (a pan-SSTR agonist for treating acromegaly and Cushing disease) with SSTR1 agonist activity (75, 76) and evaluated the potential of repurposing it to overcome ARSI resistance. Here, SSTR1 is linked to acromegaly.